

Malaysia IPO Note

25 September 2024

Industrial Products & Services | Equipment

Crest Group (CREST MK)

Testing The Waters Of Regional Expansion

- MYR0.49 FV, based on 18x FY25F P/E. Crest Group aims to raise MYR45.7m from its IPO, primarily to fund its new headquarters and business expansion plans. Our 18x P/E target is benchmarked against the automated test equipment (ATE) players and the projected 3-year earnings CAGR of 9.8% is based on the anticipated recovery of the semiconductor industry and the group's expanding presence in key markets like Thailand and China.
- Crest Group is primarily engaged in the provision of imaging, analytical, and testing solutions. These solutions are used in quality inspection, sample analysis, and R&D across various industries, such as semiconductors, electronics, automotive, oil and gas, aviation, life sciences, healthcare, as well as research and academic institutions. It also provides after-sales services.
- Expansion plans. The group has earmarked MYR15.8m from its IPO proceeds to fund the acquisition of a property for a new headquarters in Selangor, centralising its operations in Malaysia's Central region. MYR5.9m is allocated for the purchase of demonstration equipment to enhance its sales and marketing efforts. Furthermore, MYR14.5m has been set aside for regional expansion, with a focus on increasing market share in China, Thailand, and Vietnam, while targeting new industries such as healthcare and life sciences.
- Forecasts. We are projecting a 3-year earnings CAGR of 9.8%, largely supported by the semiconductor recovery, which is expected to drive increased capex spending. Additionally, the group's regional expansion, with a focus on China, Vietnam, and Thailand, should contribute towards its growth. Crest Group aims to broaden its client base across the semiconductor, E&E, academia, healthcare, and life sciences sectors, enhancing diversification and stabilising its revenue streams. Further, the group will strengthen its aftersales services, which provides a recurring income stream. Its strategic positioning within these high-growth industries and regions underpins earnings growth.
- Valuation. We ascribe an 18x P/E to the group's FY25F earnings, to arrive at a
 fair value of MYR0.49. Our target P/E is benchmarked against ATE players. Our
 target P/E represents a 30% discount to comparable peers, reflecting its
 smaller market capitalisation, lower-margin and only distribution-focused
 business model. We believe the stability of its distribution business, which
 caters to a diverse range of markets, acts as a counter-cyclical factor against
 fluctuations in the semiconductor cycle, but may not offer exciting growth
 compared to ATE peers at the same time. Additionally, its strong cash flow
 supports business expansion and the ability to dish out a minimum dividend
 payout of 30%.
- **Key risks** include order fluctuations, labour shortages, escalation of input costs, technology obsolescence and FX fluctuations.

Fair Value (Return):	MYR0.49 (+41%)
IPO Price:	MYR0.35
Closing Application Date:	25 September 2024
Indicative Listing Date	9 October 2024

Analyst

Miza Izaimi +603 2302 8121 miza.izaimi@rhbgroup.com



MYRm

Company Description

Crest Group is mainly involved in the distribution of imaging, analytical, and test equipment solutions, as well as provision of after-sales services.

IPO Details

Public issue of new shares (m)	130.7
Offer for sale of existing shares (m)	103.9
Shares outstanding (m)	865.6
Implied market cap	MYR303m

Major Shareholders (%)

Utilisation of IPO Proceeds

Climan	55.0
Lim Siong Wai	6.0
Au Chun Mun	5.7

New Headquarters	15.8
Business expansion	14.5
Purchase of demonstration equipment	5.9
Expansion of services and support team	3.6
Listing expenses	6.0

45.7

Additional Data

Listing Market	ACE
Bursa Code	0323

Forecasts and Key Data	Dec-22	Dec-23	Dec-24F	Dec-25F	Dec-26F
Total turnover (MYRm)	170.2	187.6	202.3	228.9	256.5
Recurring net profit (MYRm)	17.3	20.1	21.0	23.7	26.6
Recurring net profit growth (%)	8.7	16.3	4.6	12.8	12.3
Recurring EPS (MYR)	0.02	0.02	0.02	0.03	0.03
Recurring P/E (x)	17.5	15.1	14.4	12.8	11.4
P/BV (x)	5.6	5.0	2.5	2.2	1.9
Dividend Yield (%)	0.0	0.0	2.1	2.4	2.7
EV/EBITDA (x)	8.2	6.5	4.9	3.9	3.1
ROE (%)	33.8	33.7	18.1	17.9	17.6
Net debt to equity (%)	Net Cash				

Source: Company data. RHB

Note:

Small cap stocks are defined as companies with a market capitalisation of less than USD0.5bn.




Company Overview

Crest Group is primarily engaged in the provision of imaging, analytical, and testing solutions. These solutions are used in quality inspection, sample analysis, and R&D across various industries, such as semiconductors, electronics, automotive, oil and gas, aviation, life sciences, healthcare, and research and academic institutions.

- i. Provision of imaging, analytical and test solutions (84.98% of FY23 revenue). Imaging, analytical, and test solutions are designed for quality inspection, sample analysis, and R&D through detailed imaging and testing. These solutions allow for indepth scans and magnification to detect defects not visible to the naked eye. The group's offerings include pre-sales consulting, equipment sales and customisation, installation, commissioning, and user training;
- ii. **Provision of after-sales services (15.02% of FY23 revenue).** The group offers after-sales services, including technical support, maintenance, and the sale of spare parts and consumables. After the warranty period, customers can continue to use these services for a fee. It also supports customers that use equipment supplied by their principals, even if they did not engage Crest Group for the initial solutions.

Figure 1: Corporate structure



Source: Company data, RHB

Figure 2: Examples of products



Source: Company data, RHB



Crest Group provides imaging, analytical, and test solutions as well as after-sales services directly to end-user customers, including manufacturers and industry players in sectors such as semiconductors, electronics, automotive, oil and gas, aviation, life sciences, healthcare, as well as research and academic institutions. These customers use the group's solutions for quality inspection, sample analysis, and R&D. In addition to serving these end-users, the group also provides solutions to intermediaries, such as automation solution providers, that integrate its services into their own offerings. Furthermore, Crest Group sells equipment and after-sales services to dealers who resell them to their own customers.

Figure 3: Top customers in FY23

Customer	Principal activities	relationship (years)	Sales (MYRm)	Percentage (%)
Customer Group E	Advanced imaging; optical and portable; advanced analytical and testing; and sample management solutions	10	10.1	5.4
Customer Group G	Advanced imaging; advanced analytical and testing; and sample management solutions	7	9.2	4.9
Khon Kaen University	Advanced imaging solutions	10	5.5	2.9
Scientific and Technological Research Equipment Centre Chulalongkorn University	Advanced analytical and testing solutions	10	5.5	2.9
Tokyo Sangyo Co Ltd	Advanced imaging; advanced analytical and testing solutions	10	4.9	2.6
Total			35.1	18.7

Source: Company data, RHB

The group sources its equipment from principals and dealers. These suppliers provide the necessary imaging, analytical, and test equipment based on its proposed solutions. Additionally, for custom solutions, Crest Group may integrate equipment with third-party hardware, such as robotic arms or wafer handling systems, and third-party software, like Manufacturing Execution Systems (MES). These third-party components are either developed by service providers or purchased directly from its principals.

Figure 4: Top suppliers in FY23

Supplier	Equipment sourced	Length of relationship (years)	Purchases (MYRm)	Percentage (%)
Supplier Group A	Advanced imaging; optical and portable; advanced analytical and testing; and sample management equipment	8	51.9	40.9
Supplier Group B	Advanced imaging; optical and portable; advanced analytical and testing; and sample management equipment	8	30.1	23.7
Supplier Group D	Advanced imaging equipment	16	4.8	3.8
Supplier Group C	Optical and portable; and advanced analytical and testing equipment	11	4.0	3.2
Ulvac-Phi, Inc	Advanced analytical and testing equipment	10	2.5	2.0
Total			93.2	73.5

Source: Company data, RHB

The group is led by an experienced and technically skilled key management team, with an average of 28 years of industry experience and in-depth knowledge of its business operations. Lim Siong Wai (Managing Director), Au Chun Mun (Executive Director), and Yap Kian Meng (Executive Director) possess the relevant background in science, which they have leveraged to build and expand the group's imaging, analytical, and test business over the years. The management team has strong industry and functional expertise, developed through years of experience in their respective fields. They also take an active, hands-on approach in leading their departments to drive the group's growth.



Future Plans and Strategies

New headquarters in Selangor for operations in central region of Malaysia. The group plans to use MYR15.8m of its IPO proceeds to partially fund the acquisition of a property to establish a new headquarters in Selangor, centralising its operations in the Central region of Malaysia. Currently operating from three rented premises in Puchong and Subang Jaya, it aims to relocate to a commercial or light industrial property of approximately 1,858 sq m in the Klang Valley. The total cost for the new HQ is c.MYR20m. An additional MYR3.6m will be allocated from internal funds for renovations and equipment purchases.

Management plans to purchase the property within 36 months after listing and begin renovations immediately. The new headquarters will streamline operations, improve management, and provide expanded space for future growth. It will also feature a demonstration room of 186 sq m for showcasing new equipment and conducting internal employee training. This centralisation and expansion will support the company's future growth and business expansion in Malaysia.

New additional demonstration equipment in Malaysia, China and Thailand offices. The group aims to enhance its sales and marketing activities by upgrading its demonstration rooms in Malaysia, Singapore, China, and Thailand, where customers can experience the features and capabilities of the latest equipment. To stay competitive and keep up with technological advancements, it plans to purchase new models of demonstration equipment as they are introduced to the market. Outdated or obsolete equipment will either be replaced or sold to customers.

It has allocated MYR5.9m from its IPO proceeds to purchase the latest equipment models over the next 36 months. This will help provide better customer experience and further support the company's growth and business expansion.

Expanding its overseas presence by establishing a new branch office in Ho Chi Minh City to tap into Vietnam's growing imaging, analysis, and testing industry, valued at USD1.9bn in 2023. The company has seen increasing revenue from Vietnam and aims to expand its 0.02% market share by capitalising on growing demand. Moreover, it plans to open new branch offices in Chengdu and Shenzhen to grow the business in China, where the industry is valued at CNY202.7bn in 2023. The company has captured a 0.03% market share and plans to increase this by expanding its customer base and improving its service to local clients. These offices will complement the existing Suzhou office. Crest Group will also hire a new team to target life sciences and healthcare customers in Thailand, which will allow it to diversify and expand its offerings in Thailand.

The setup of new offices (Vietnam, Chengdu, and Shenzhen) will cost c.MYR1.3m, covering rental, renovations, and equipment, and will be funded entirely by IPO proceeds. These offices are expected to be operational within 36 months of the IPO. Additionally, the group plans to hire new personnel for these offices and strengthen its team in Thailand.

Expanding services and support team. Crest Group aims to expand its technical support and maintenance services by increasing its service and support team. This expansion focuses on strengthening the after-sales segment, which contributed between 15.0% and 26.3% of total revenue in recent financial years. It will hire two new service managers: one in Selangor and one in Penang to manage technical support operations. Additionally, the group is looking to hire eight new service personnel: five in Selangor and one each in its offices in China, Thailand, and Singapore. The estimated cost for this expansion over the first three years is MYR3.6m, which will be fully funded by the IPO proceeds. This strategic hiring will enhance its service capacity, improve financial performance through additional recurring income, and strengthen its after-sales business segment.



Financial Overview And Valuation

Financial overview. Crest Group's FY20-23 revenue CAGR of 14.7% was mainly driven by the provision of imaging, analytical, and test solutions segment, with significant growth from Thailand and China, with both countries achieving individual revenue CAGRs of 25% during this period. These two markets together contributed 51.1% of FY23 revenue, surpassing Malaysia's share. The group's core earnings (excluding one-off listing expenses) recorded a 3-year CAGR of 18.8%, with margin improving slightly to 10.7% in FY23 from 9.6% in FY20.

Dividends. Crest Group has a 30% dividend payout policy. Assuming a consistent payout ratio, projected DPS for FY24-26 is in the 0.7-0.9 sen range, implying c.2.1-2.7% yield at the IPO price.

Earnings forecasts. We are projecting a 3-year earnings CAGR of 9.8%, largely supported by the semiconductor recovery, which is expected to drive increased capex spending. Additionally, the group's regional expansion, with a focus on China, Vietnam, and Thailand, should contribute to growth. Crest Group aims to broaden its client base across the semiconductor, E&E, academia, healthcare, and life sciences sectors, enhancing diversification and stabilising its revenue streams. Furthermore, the company will strengthen its after-sales services, which provides a recurring income stream. Management believes strategic positioning within these high-growth industries and regions underpins earnings growth.

Figure 5: Revenue trend





Figure 6: Core earnings trend



Source: Company data, RHB

Source: Company data, RHB

Figure 7: FY23 revenue breakdown





Figure 8: FY23 gross profit breakdown



Source: Company data, RHB

Source: Company data, RHB



Valuation. We ascribe 18x P/E to the group's FY25F earnings, to arrive at a fair value of MYR0.49. Our target P/E is benchmarked against ATE players, but the group's operations align more closely with QES Group, as both companies focus primarily on distributorship. Our target P/E represents a 30% discount to comparable peers, reflecting its smaller market capitalisation and lower-margin contributions from the distribution segment. We believe the stability of its distribution business, which caters to a diverse range of markets, acts as a counter-cyclical factor against fluctuations in the semiconductor cycle, but may not offer exciting growth compared to the ATE peers at the same time. Additionally, its strong cash flow supports business expansion, and ability to dish out a minimum dividend payout of 30%.

Figure 9: Peer comparison

	FYE	Share price	Mkt cap		P/E (x)		EV/ EBITDA (x)	EPS gro	wth (%)	ROE (%)	Dvd. yld (%)
		(MYR)	(MYRm)	Actual	1-yr fwd	2-yr fwd	1-yr fwd	1-yr fwd	2-yr fwd	1-yr fwd	1-yr fwd
Crest Group	Dec	0.35	303.0	15.1	14.4	12.8	4.9	4.6	12.8	18.1	2.1
Related peers											
ViTrox Corp	Dec	3.35	6337.6	49.4	48.0	32.5	37.5	3.0	47.7	13.8	0.6
Greatech	Dec	2.2	5521.4	35.8	29.1	24.3	23.3	22.8	20.1	25.2	na
Pentamaster Corp	Dec	3.68	2617.6	29.4	28.3	23.0	14.8	3.8	23.2	9.2	0.6
Mi Technovation	Dec	1.96	1750.1	31.8	23.6	19.7	12.6	34.4	20.3	6.9	2.2
QES Group	Dec	0.56	467.1	25.3	21.0	17.6	11.3	20.2	19.4	12.4	1.1
TT Vision Holdings	Dec	0.84	402.4	37.5	37.6	18.0	24.1	-0.3	108.4	10.5	na
Elsoft Research	Dec	0.45	308.1	43.9	39.5	19.9	26.7	11.0	98.7	5.8	1.1
Aemulus Holdings	Sep	0.28	188.0	-3.4	na	na	na	na	na	na	na
MMS Ventures	Dec	0.48	95.3	-30.9	na	na	na	na	na	na	na
VisDynamics Holdings	Oct	0.33	86.7	30.6	na	na	na	na	na	na	na
Mkt. Cap Weighted Avg.				38.4	35.5	26.2	25.9	13.1	34.0	15.8	0.6
Simple Average				24.9	32.5	22.1	21.5	13.6	48.2	12.0	8.0

Source: Company data, RHB, Bloomberg

IPO Details

Figure 10: Indicative IPO timeline

Opening of Application	18 September 2024
Closing of Application	25 September 2024
Balloting of applications	30 September 2024
Allotment of the IPO Shares to successful applicants	7 October 2024
Listing	9 October 2024

Source: Company data, RHB

Figure 11: Utilisation of IPO proceeds

	Estimated timeframe	MYRm	% of proceeds
Setup of a new centralised headquarters	Within 36 months	15.8	34.5
Business expansion	Within 36 months	14.5	31.7
Purchase of additional demonstration equipment	Within 36 months	5.9	12.8
Expansion of technical support and maintenance team	Within 36 months	3.6	7.9
Listing expenses	Within 3 months	6.0	13.1
Total	<u></u>	45.7	100.0

Source: Company data, RHB

Figure 12: Offering structure

	No. of IPO shares	% of enlarged share base [*]
Public Issue of new shares:		
Malaysian public	43,280,000	5.0
Pink Form allocations	12,984,000	1.5
Bumiputera	74,441,300	8.6
	130,705,300	15.1
Offer for sale:		
Private placement to selected investors	103,890,000	12.0
Total	234,595,300	27.1

Note: Based on the enlarged issued share capital of 865,598,000 shares after IPO Source: Company data, RHB

Key Risks

- i. Dependent on the ability to maintain business relationship with existing customers and to secure new customers;
- ii. Reliant on equipment principals;
- iii. Subject to technology advance and evolution;
- Exposure to FX fluctuation; iv.
- Dependent towards key senior management for the continued success of the group. ٧.



RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report may contain comments, estimates, projections, forecasts and expressions of opinion relating to macroeconomic research published by RHB economists of which should not be considered as investment ratings/advice and/or a recommendation by such economists on any securities discussed in this report.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and

other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the companylies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.



Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.

Indonesia

This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing Indonesian laws and regulations.

Singapore

This report is issued and distributed in Singapore by RHB Bank Berhad (through its Singapore branch) which is an exempt capital markets services entity and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Bank Berhad (through its Singapore branch) may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Bank Berhad (through its Singapore branch) accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Bank Berhad (through its Singapore branch) in respect of any matter arising from or in connection with the report.

This report was prepared by RHB is meant for distribution solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act") via a registered U.S. broker-dealer as appointed by RHB from time to time. Accordingly, any access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors (via a registered U.S broker-dealer), nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and currently has not appointed a U.S. broker-dealer. Additionally, RHB does not offer brokerage services to U.S. persons. Any order for the purchase or sale of all securities discussed herein must be placed with and through a registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. For avoidance of doubt, RHB reiterates that it has not appointed any U.S. broker-dealer during the issuance of this report. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of any registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with, hold any positions in the securities and/or capital market products (including but not limited to shares, warrants, and/or derivatives), trade or otherwise effect transactions for its own account or the account of its customers or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered in this research report.

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

In Singapore, investment research activities are conducted under RHB Bank Berhad (through its Singapore branch), and the disclaimers above similarly apply.

Malavsia

Save as disclosed in the following link RHB Research Conflict Disclosures - Sep 2024 and to the best of our knowledge, RHBIB hereby declares that:

- RHBIB does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHBIB is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
 - *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHBIB did not receive compensation for investment banking or corporate finance
- services from the subject company in the past 12 months. RHBIB did not receive compensation or benefit (including gift and special cost
- arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Thailand

Save as disclosed in the following link RHB Research Conflict Disclosures - Sep 2024 and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:

- RHB Securities (Thailand) PCL does not have a financial interest in the securities or other capital market products of the subject company(ies) covered in this report.
- RHB Securities (Thailand) PCL is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Save as disclosed in the following link RHB Research Conflict Disclosures - Sep 2024 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report. For the avoidance of doubt, interest in securities include the following:
 - Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the subject company's securities covered in this report*;
 - Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*
 - Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.
 - Managing or jointly with other parties managing such parties as referred to in (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a director or board member* of the subject company(ies) covered in this report.
- PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only.

**The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Singapore

Save as disclosed in the following link RHB Research Conflict Disclosures - Sep 2024 and to the best of our knowledge, the Singapore Research department of RHB Bank Berhad (through its Singapore branch) hereby declares that:

- RHB Bank Berhad, its subsidiaries and/or associated companies do not make a market in any issuer covered by the Singapore research analysts in this report.
- 2. RHB Bank Berhad, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad's Singapore research staff or connected persons do not serve on the board or trustee positions of the issuer covered by the Singapore research analysts in this report.
- RHB Bank Berhad, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered by the Singapore research analysts in this report or any other relationship that may create a potential conflict of interest.
- RHB Bank Berhad's Singapore research analysts, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered by the Singapore research analysts in this report.



6. RHB Bank Berhad's Singapore research analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation on the issuer covered by the Singapore research analysts.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:
(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd Level 3A, Tower One, RHB Centre

Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel:+603 9280 8888 Fax:+603 9200 2216

BANGKOK

RHB Securities (Thailand) PCL

10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500 Thailand

Tel: +66 2088 9999 Fax:+66 2088 9799

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD Jl. Jendral Sudirman Kav 52-53 Jakarta 12190 Indonesia

Tel: +6221 509 39 888 Fax: +6221 509 39 777

SINGAPORE

RHB Bank Berhad (Singapore branch)

90 Cecil Street #04-00 RHB Bank Building Singapore 069531 Fax: +65 6509 0470

